RTKN2

Across TCGA pan-cancer cohorts, RTKN2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of RTKN2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RTKN2 RNA is repressed in tumor relative to normal tissue. In most cancer types RTKN2 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and BLCA are the cancer types where RTKN2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RTKN2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−4.729	<.001	9	view →
LUSC	Female	II,III,IV	−4.097	<.001	9	view →
BLCA	Male	All	+1.830	<.001	8	view →
STAD	All	II,III,IV	+1.303	<.001	8	view →
COAD	Male	All	+0.694	<.001	8	view →
KIRP	All	II,III,IV	+0.502	<.001	8	view →
KICH	Female	All	−0.469	<.001	7	view →
UCEC	All	II,III,IV	+2.540	<.001	6	view →
BRCA	All	II,III,IV	+1.258	<.001	6	view →
LIHC	Female	All	+0.381	<.001	6	view →
CHOL	Male	All	+1.553	<.001	3	view →
PRAD	All	All	+0.484	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

RTKN2–LUAD

Open the LUAD breakdown →